Neurovalens, a health-tech company specializing in neurotechnology, has launched Modius Sleep, a non-invasive device cleared by the FDA for the treatment of chronic insomnia. This product launch marks the company's entry into the U.S. market with a physician-prescribed solution that aims to improve sleep quality without the use of drugs.
Modius Sleep: A Non-Invasive Approach to Insomnia
Modius Sleep employs electrical vestibular nerve stimulation (VeNS) to modulate brain activity related to sleep. The device, a headset worn for 30 minutes each evening, delivers low-level electrical signals to the vestibular nerve, influencing the hypothalamus and brainstem, which are key areas for regulating circadian rhythm and sleep patterns.
Dr. Jason McKeown, CEO of Neurovalens, expressed his concern about the reliance on sleeping pills and sedatives among his patients and emphasized the need for a better solution. "Sleep is critically important to our overall health," said Dr. McKeown. "The truth is these medications weren’t working, and I knew there was a better way to treat chronic insomnia and other sleep disorders through my research and training in neurotechnology."
Clinical Trial Results
A clinical trial published in Brain Stimulation demonstrated that 95% of participants experienced improved sleep after four weeks of using Modius Sleep. This suggests a significant potential for the device to offer relief to individuals struggling with chronic insomnia.
How to Access Modius Sleep
Patients interested in Modius Sleep must complete a questionnaire on the Neurovalens website to determine eligibility. If qualified, they will be connected with a physician through the Neurovalens online platform to obtain a prescription. The device retails for $1,185 and may be eligible for purchase using HSA/FSA funds. Neurovalens also provides resources to help patients seek reimbursement from their insurance providers.
The Need for Novel Insomnia Treatments
Chronic insomnia affects a significant portion of the adult population, leading to impaired daytime function, reduced quality of life, and increased risk of various health problems. Current treatments often involve pharmacological interventions, which can have side effects and may not be effective for all individuals. Non-pharmacological approaches like cognitive behavioral therapy for insomnia (CBT-I) are also used, but access can be limited. Modius Sleep offers a new, non-invasive option that could potentially fill an unmet need in the management of chronic insomnia.
